Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Rating of "Buy" from Brokerages

Key Points

• Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received an average rating of "Buy" from twelve brokerages, with eleven recommending a buy and one a strong buy.
• The average target price for PVLA among analysts is $60.91, with several firms providing target prices ranging from $56.00 to $85.00.
• Palvella's stock has seen a recent decline of 3.9% and reported a quarterly EPS of ($0.86), which missed expectations by $0.08.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average recommendation of "Buy" from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $60.9091.

Several research firms have recently commented on PVLA. Oppenheimer began coverage on shares of Palvella Therapeutics in a research report on Tuesday, September 9th. They issued an "outperform" rating and a $85.00 target price for the company. Chardan Capital raised their target price on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Truist Financial began coverage on shares of Palvella Therapeutics in a research report on Monday, July 21st. They issued a "buy" rating and a $56.00 target price for the company. Canaccord Genuity Group raised their target price on shares of Palvella Therapeutics from $52.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, August 19th. Finally, HC Wainwright raised their target price on shares of Palvella Therapeutics from $38.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, August 15th.

Palvella Therapeutics Stock Down 3.9%

Shares of PVLA opened at $54.63 on Tuesday. The stock has a market capitalization of $604.21 million, a P/E ratio of -4.51 and a beta of -0.04. The firm has a fifty day simple moving average of $43.36 and a two-hundred day simple moving average of $30.82. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $61.48.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Sell-side analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $37,000. Spire Wealth Management bought a new position in shares of Palvella Therapeutics in the 1st quarter worth about $70,000. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $85,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $104,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.